Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2012, Article ID 543062, 11 pages
http://dx.doi.org/10.1155/2012/543062
Research Article

Influence of Angiotensin II Subtype 2 Receptor ( R) Antagonist, PD123319, on Cardiovascular Remodelling of Aged Spontaneously Hypertensive Rats during Chronic Angiotensin II Subtype 1 Receptor ( R) Blockade

1Department of Pharmacology, Monash University, Clayton, VIC 3800, Australia
2Department of Anatomy and Cell Biology, Monash University, Clayton, VIC 3800, Australia

Received 19 September 2011; Accepted 11 November 2011

Academic Editor: Anderson J. Ferreira

Copyright © 2012 Emma S. Jones et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. G. Lakatta and D. Levy, “Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease,” Circulation, vol. 107, no. 2, pp. 346–354, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Swynghedauw, “Molecular mechanisms of myocardial remodeling,” Physiological Reviews, vol. 79, no. 1, pp. 215–262, 1999. View at Google Scholar · View at Scopus
  3. M. A. Gaballa, C. T. Jacob, T. E. Raya, J. Liu, B. Simon, and S. Goldman, “Large artery remodeling during aging: biaxial passive and active stiffness,” Hypertension, vol. 32, no. 3, pp. 437–443, 1998. View at Google Scholar · View at Scopus
  4. D. Susic, E. Nunez, K. Hosoya, and E. D. Frohlich, “Coronary hemodynamics in aging spontaneously hypertensive and normotensive Wistar-Kyoto rats,” Journal of Hypertension, vol. 16, no. 2, pp. 231–237, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and T. Unger, “International union of pharmacology. XXIII. The angiotensin II receptors,” Pharmacological Reviews, vol. 52, no. 3, pp. 415–472, 2000. View at Google Scholar · View at Scopus
  6. M. Wang, B. Khazan, and E. Lakatta, “Central arterial aging and angiotensin II signaling,” Current Hypertension Reviews, vol. 6, no. 4, pp. 266–281, 2010. View at Publisher · View at Google Scholar
  7. E. S. Jones, A. Vinh, C. A. McCarthy, T. A. Gaspari, and R. E. Widdop, “AT2 receptors: functional relevance in cardiovascular disease,” Pharmacology and Therapeutics, vol. 120, no. 3, pp. 292–316, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Akishita, M. Iwai, L. Wu et al., “Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice,” Circulation, vol. 102, no. 14, pp. 1684–1689, 2000. View at Google Scholar · View at Scopus
  9. S. Ichihara, T. Senbonmatsu, E. Price Jr., T. Ichiki, F. A. Gaffney, and T. Inagami, “Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension,” Circulation, vol. 104, no. 3, pp. 346–351, 2001. View at Google Scholar · View at Scopus
  10. S. Kurisu, R. Ozono, T. Oshima et al., “Cardiac angiotensin II type 2 receptor activates the Kinin/NO system and inhibits fibrosis,” Hypertension, vol. 41, no. 1, pp. 99–107, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. R. E. Widdop, E. S. Jones, R. E. Hannan, and T. A. Gaspari, “Angiotensin AT2 receptors: cardiovascular hope or hype?” British Journal of Pharmacology, vol. 140, no. 5, pp. 809–824, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. D. You, L. Loufrani, C. Baron, B. I. Levy, R. E. Widdop, and D. Henrion, “High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats,” Circulation, vol. 111, no. 8, pp. 1006–1011, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. H. Liu, X. P. Yang, V. G. Sharov et al., “Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors,” Journal of Clinical Investigation, vol. 99, no. 8, pp. 1926–1935, 1997. View at Google Scholar · View at Scopus
  14. B. S. Tea, S. Der Sarkissian, R. M. Touyz, P. Hamet, and D. DeBlois, “Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo,” Hypertension, vol. 35, no. 5, pp. 1069–1073, 2000. View at Google Scholar · View at Scopus
  15. J. Varagic, D. Susic, and E. D. Frohlich, “Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors,” Hypertension, vol. 37, no. 6, pp. 1399–1403, 2001. View at Google Scholar · View at Scopus
  16. S. Busche, S. Gallinat, R. M. Bohle et al., “Expression of angiotensin AT1 and AT2 receptors in adult rat cardiomyocytes after myocardial infarction: a single-cell reverse transcriptase-polymerase chain reaction study,” American Journal of Pathology, vol. 157, no. 2, pp. 605–611, 2000. View at Google Scholar · View at Scopus
  17. Y. Tsutsumi, H. Matsubara, N. Ohkubo et al., “Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression,” Circulation Research, vol. 83, no. 10, pp. 1035–1046, 1998. View at Google Scholar · View at Scopus
  18. J. J. Lopez, B. H. Lorell, J. R. Ingelfinger et al., “Distribution and function of cardiac angiotensin AT1-and AT2-receptor subtypes in hypertrophied rat hearts,” American Journal of Physiology, vol. 267, no. 2, part 2, pp. H844–H852, 1994. View at Google Scholar · View at Scopus
  19. N. Ohkubo, H. Matsubara, Y. Nozawa et al., “Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism,” Circulation, vol. 96, no. 11, pp. 3954–3962, 1997. View at Google Scholar · View at Scopus
  20. C. Heymes, J. S. Silvestre, C. Llorens-Cortes et al., “Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes,” Endocrinology, vol. 139, no. 5, pp. 2579–2587, 1998. View at Google Scholar · View at Scopus
  21. R. E. Widdop, A. Vinh, D. Henrion, and E. S. Jones, “Vascular angiotensin AT2 receptors in hypertension and ageing,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 4, pp. 386–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Heymes, B. Swynghedauw, and B. Chevalier, “Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats,” Circulation, vol. 90, no. 3, pp. 1328–1333, 1994. View at Google Scholar · View at Scopus
  23. N. Basso, R. Cini, A. Pietrelli, L. Ferder, N. A. Terragno, and F. Inserra, “Protective effect of long-term angiotensin II inhibition,” American Journal of Physiology, vol. 293, no. 3, pp. H1351–H1358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Linz, H. Heitsch, B. A. Scholkens, and G. Wiemer, “Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats,” Hypertension, vol. 35, no. 4, pp. 908–913, 2000. View at Google Scholar · View at Scopus
  25. O. H. Bing, W. W. Brooks, K. G. Robinson et al., “The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure,” Journal of Molecular and Cellular Cardiology, vol. 27, no. 1, pp. 383–396, 1995. View at Google Scholar · View at Scopus
  26. E. S. Jones, M. J. Black, and R. E. Widdop, “Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade,” Journal of Molecular and Cellular Cardiology, vol. 37, no. 5, pp. 1023–1030, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. C. I. Johnston, J. A. Millar, D. J. Casley, B. P. McGrath, and P. G. Matthews, “Hormonal responses to angiotensin blockade. Comparison between receptor antagonism and converting enzyme inhibition,” Circulation Research, vol. 46, no. 6, pp. I128–I134, 1980. View at Google Scholar · View at Scopus
  28. N. Makino, M. Sugano, S. Otsuka, and T. Hata, “Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats,” Hypertension, vol. 30, no. 4, pp. 796–802, 1997. View at Google Scholar · View at Scopus
  29. B. Gigante, O. Piras, P. De Paolis, A. Porcellini, A. Natale, and M. Volpe, “Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats,” Journal of Hypertension, vol. 16, no. 12, part 2, pp. 2039–2043, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. H. M. Siragy, M. de Gasparo, and R. M. Carey, “Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats,” Hypertension, vol. 35, no. 5, pp. 1074–1077, 2000. View at Google Scholar · View at Scopus
  31. L. M. Duke, R. G. Evans, and R. E. Widdop, “AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats,” American Journal of Physiology, vol. 288, no. 5, pp. H2289–H2297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. N. Barber, D. B. Sampey, and R. E. Widdop, “AT2 receptor stimulation enhances antihypertensive effect of AT1 receptor antagonist in hypertensive rats,” Hypertension, vol. 34, no. 5, pp. 1112–1116, 1999. View at Google Scholar · View at Scopus
  33. R. M. Carey, N. L. Howell, X. H. Jin, and H. M. Siragy, “Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats,” Hypertension, vol. 38, no. 6, pp. 1272–1277, 2001. View at Google Scholar · View at Scopus
  34. X. C. Li and R. E. Widdop, “AT2 receptor-mediated vasodilatation is unmasked by AT 1 receptor blockade in conscious SHR,” British Journal of Pharmacology, vol. 142, no. 5, pp. 821–830, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Bosnyak, I. K. Welungoda, A. Hallberg, M. Alterman, R. E. Widdop, and E. S. Jones, “Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats,” British Journal of Pharmacology, vol. 159, no. 3, pp. 709–716, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. J. B. Michel, D. Heudes, O. Michel et al., “Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries,” American Journal of Physiology, vol. 267, no. 1, part 2, pp. R124–R135, 1994. View at Google Scholar · View at Scopus
  37. M. M. Thompson, T. T. Oyama, F. J. Kelly, T. M. Kennefick, and S. Anderson, “Activity and responsiveness of the renin-angiotensin system in the aging rat,” American Journal of Physiology, vol. 279, no. 5, pp. R1787–R1794, 2000. View at Google Scholar · View at Scopus
  38. A. Biernacka and N. G. Frangogiannis, “Aging and cardiac fibrosis,” Aging and Disease, vol. 2, no. 2, pp. 158–173, 2011. View at Google Scholar
  39. H. Sugino, R. Ozono, S. Kurisu et al., “Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice,” Hypertension, vol. 37, no. 6, pp. 1394–1398, 2001. View at Google Scholar · View at Scopus
  40. J. Xu, O. A. Carretero, Y. H. Liu et al., “Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice,” Hypertension, vol. 40, no. 3, pp. 244–250, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. O. J. Tsotetsi, A. J. Woodiwiss, M. Netjhardt, D. Qubu, R. Brooksbank, and G. R. Norton, “Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats,” Hypertension, vol. 38, no. 4, pp. 846–851, 2001. View at Google Scholar · View at Scopus
  42. D. Badenhorst, M. Maseko, O. J. Tsotetsi et al., “Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats,” Cardiovascular Research, vol. 57, no. 3, pp. 632–641, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. J. DeGroot, “The AGE of the matrix: chemistry, consequence and cure,” Current Opinion in Pharmacology, vol. 4, no. 3, pp. 301–305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Kuzuya, T. Asai, S. Kanda, K. Maeda, X. W. Cheng, and A. Iguchi, “Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice,” Diabetologia, vol. 44, no. 4, pp. 433–436, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Robert, S. Besse, A. Sabri et al., “Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart,” Laboratory Investigation, vol. 76, no. 5, pp. 729–738, 1997. View at Google Scholar · View at Scopus
  46. L. Wu, M. Iwai, H. Nakagami et al., “Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 1, pp. 49–54, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. K. T. Weber, “Angiotensin II and connective tissue: homeostasis and reciprocal regulation,” Regulatory Peptides, vol. 82, no. 1–3, pp. 1–17, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Benetos and M. E. Safar, “Aortic collagen, aortic stiffness, and AT1 receptors in experimental and human hypertension,” Canadian Journal of Physiology and Pharmacology, vol. 74, no. 7, pp. 862–866, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Lacolley, M. E. Safar, B. Lucet, K. Ledudal, C. Labat, and A. Benetos, “Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 662–667, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. P. E. Walters, T. A. Gaspari, and R. E. Widdop, “Angiotensin-(1–7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats,” Hypertension, vol. 45, no. 5, pp. 960–966, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Bosnyak, E. S. Jones, A. Christopolous, M. I. Aguilar, W. G. Thomas, and R. E. Widdop, “Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors,” Clinical Science, vol. 121, pp. 297–303, 2011. View at Google Scholar